GROWTH · PEPTIDE
What is CJC-1295?
Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026
THE SHORT ANSWER
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It signals the pituitary to release more growth hormone. It exists in two forms: one without DAC that lasts about 30 minutes, and one with DAC that lasts about a week.
CJC-1295 at a glance
- Type
- Peptide
- Also known as
- Mod GRF 1-29, CJC-1295 no DAC, CJC-1295 DAC
- Mechanism
- GHRH analog (no DAC / Mod GRF 1-29)
- Status
- Compounded (Rx)
- Half-life
- ~30 minutes
- Route
- Subcutaneous
- Dosing range in the literature
- 100–300 mcg per dose
- Onset
- 1–2 weeks (sleep); 6–12 weeks (composition)
- Storage
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date
How CJC-1295 works
It binds the GHRH receptor on the pituitary. Four amino acid changes protect it from rapid breakdown. The DAC version adds a group that binds albumin in the blood, greatly extending how long it acts.
What CJC-1295 is studied for
- Growth hormone release
- Sleep quality
- Body composition
Human studies show sustained increases in growth hormone and IGF-1. It was not developed further as a medicine, so outcome data on body composition is limited.
Being studied for something is not proof that it works. Results in individuals vary.
CJC-1295 dosing
Published protocols describe 100–300 mcg per dose, 1–3× daily, typically bedtime, given subcutaneous. Onset is typically reported at 1–2 weeks (sleep); 6–12 weeks (composition).
These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.
CJC-1295 side effects and risks
- Water retention
- Tingling
- Headache
- Flushing
Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.
Is CJC-1295 FDA approved?
Not FDA-approved.
Approval and trial status change. This page was last reviewed on October 1, 2026.
CJC-1295 at G1 Peptides
G1 Peptides supplies CJC-1295 as vials (In CJC/Ipamorelin blend) and in pens (Apex, Apex Plus, Trinity Stack, Fragment Apex, Lean Recovery). Prescription products ship only after a licensed provider has reviewed the order.
CJC-1295 questions
- What is CJC-1295?
- CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It signals the pituitary to release more growth hormone. It exists in two forms: one without DAC that lasts about 30 minutes, and one with DAC that lasts about a week.
- What is CJC-1295 used for?
- CJC-1295 is studied for growth hormone release, sleep quality, and body composition. Human studies show sustained increases in growth hormone and IGF-1. It was not developed further as a medicine, so outcome data on body composition is limited.
- How does CJC-1295 work?
- It binds the GHRH receptor on the pituitary. Four amino acid changes protect it from rapid breakdown. The DAC version adds a group that binds albumin in the blood, greatly extending how long it acts.
- Is CJC-1295 FDA approved?
- Not FDA-approved.
- What is the typical CJC-1295 dosage?
- Published protocols describe 100–300 mcg per dose, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
- What are the side effects of CJC-1295?
- Risks noted for CJC-1295 include water retention, tingling, headache, and flushing. Tell your provider about your medications and conditions before starting.
- What is the half-life of CJC-1295?
- The reported half-life is ~30 minutes. Onset is typically reported at 1–2 weeks (sleep); 6–12 weeks (composition).
- How should CJC-1295 be stored?
- Refrigerated (2–8 °C); use within the pharmacy beyond-use date.
For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.